NSCLC (Advanced Non-small Cell Lung Cancer)Phase 2NCT07669051
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
A Phase 2 study testing ivonescimab plus EGFR-TKI. in people with NSCLC (Advanced Non-small Cell Lung Cancer), run by Shandong Cancer Hospital and Institute at 1 site in China.
Trial summary
This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after prior EGFR-TKI therapy. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- NSCLC (Advanced Non-small Cell Lung Cancer)
- What is being tested?
- ivonescimab plus EGFR-TKI.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2026to 1 Jan 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Voluntarily signed written informed consent form; 2. Age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 4. Expected survival ≥ 3 months; 5. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC), which is unresectable for complete surgical resection and not eligible for radical concurrent/sequential chemoradiotherapy, staged per the 8th edition TNM Staging for Lung Cancer released by the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC); 6. Positive EGFR sensitive activating mutation confirmed by tumor histology, cytology or hematology testing before enrollment, including exon 19 deletion (19Del) and exon 21 point mutation (L858R); patients with EGFR T790M mutation are also eligible for enrollment; 7. Developed slow progression or potential progression during EGFR-TKI therapy: 8. Presence of at least one measurable lesion; 9. Normal function of major organs, meeting all the following criteria:
- Routine blood test results meet the requirements (no blood transfusion, no use of hematopoietic growth factors, no drug correction within 14 days before testing):
- Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L (1,500/mm³); b. Platelet count (PLT) ≥ 90×10⁹/L (90,000/mm³); c. Hemoglobin (HB) ≥ 90 g/L; 10. Biochemical test results meet the following criteria:
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN;
- Serum albumin (ALB) ≥ 28 g/L;
- Serum creatinine (sCr) ≤ 1.5×ULN; urine protein < 2+ or 24-hour urinary total protein quantification < 1.0 g (creatinine clearance calculated per Cockcroft-Gault formula); Coagulation function meets the requirements: International Normalized Ratio (INR) ≤ 1.5×ULN and activated partial thromboplastin time (APTT) ≤ 1.5×ULN;
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after prior EGFR-TKI therapy.
Read the detailed description
This is a prospective, single-center, Phase II clinical study. The study plans to enroll a total of 36 patients, all diagnosed with advanced NSCLC who developed slow progression or potential progression after failure of EGFR-TKI therapy. The objective of this study is to investigate the efficacy and safety of ivonescimab combined with EGFR-TKIs in patients with advanced NSCLC presenting with the specific progression patterns after prior EGFR-TKI therapy.
The study design is divided into two stages: The first stage is the safety lead-in phase, which plans to enroll 6 subjects. All subjects will receive ivonescimab in combination with their original EGFR-TKI regimen. After the last enrolled subject completes at least 21 days of observation following their first dose of study treatment, investigators will conduct a safety assessment and decide whether to enter the expansion phase with the current dose regimen. If the safety and tolerability profile is unacceptable, investigators will decide to revise or terminate the study, and may adjust the dosing regimen of ivonescimab and/or EGFR-TKIs. A total of 30 subjects are planned to be enrolled in the expansion phase.
All enrolled patients will receive ivonescimab in combination with their original EGFR-TKI regimen, with every 3 weeks constituting one treatment cycle. Treatment will continue until disease progression, intolerable toxicity, investigator-initiated discontinuation, patient withdrawal of informed consent, or meeting other treatment discontinuation criteria specified in the protocol, whichever occurs first. During treatment, investigators will determine disease progression (PD) based on tumor response evaluated per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and decide whether the patient may continue study treatment. If the patient's performance status remains stable and the investigator judges that the patient can benefit from continued treatment, the patient may continue on study treatment. During the study, clinical tumor imaging assessment will be performed by investigators per RECIST v1.1 in accordance with routine clinical practice. For patients who discontinue treatment for reasons other than disease progression, follow-up of disease status will continue whenever possible until the patient initiates other anti-tumor therapy, develops disease progression, withdraws informed consent, dies, or the study concludes, whichever occurs first.
Investigators will assess the safety of ivonescimab in this study population. All adverse events (AEs) will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0), and the causal relationship between adverse events and study treatment will be determined.
- Being tested
- ivonescimab plus EGFR-TKI.
- Keywords
- Ivonescimab, gradual progression, potential progression
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ivonescimab plus EGFR-TKI.Drug
All subjects will receive ivonescimab in combination with their original EGFR-TKI regimen.
| Study group | Role | What they receive |
|---|---|---|
| Arm1 | Experimental | All subjects will receive ivonescimab in combination with their original EGFR-TKI regimen. Receives: Drug: ivonescimab plus EGFR-TKI. |
What is being measured
The primary outcome is the main question the study is designed to answer.
PFS
PFS was defined as the interval from diagnosis to disease progression or death from any cause.
Measured: From randomization through to the end of study, planned duration was 20 months
Secondary outcomes (1)
OS
OS was defined as the time from diagnosis to death from any cause.
Measured: From randomization through to the end of study, planned duration was 20 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2026
- Study start1 Jan 2026
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NSCLC (Advanced Non-small Cell Lung Cancer)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jinming Yu, Shandong Cancer Hospital and Institute
- Investigators
- Jinming Yu, Dr, Study director, Shandong Cancer Hospital and Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07669051
- Sponsor's protocol ID
- SDZLEC2025-480-02
- Status last verified
- Jun 2026
- First submitted
- 2 Jun 2026
- Last updated
- 25 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
- ClinicalTrials.gov ID
- NCT07669051
- Acronym / sponsor ID
- SDZLEC2025-480-02
- Keywords
- Ivonescimab, gradual progression, potential progression
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Shandong Cancer Hospital and InstituteUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Jan 2029 (estimated)
- First posted
- 25 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after prior EGFR-TKI therapy.
Detailed description
This is a prospective, single-center, Phase II clinical study. The study plans to enroll a total of 36 patients, all diagnosed with advanced NSCLC who developed slow progression or potential progression after failure of EGFR-TKI therapy. The objective of this study is to investigate the efficacy and safety of ivonescimab combined with EGFR-TKIs in patients with advanced NSCLC presenting with the specific progression patterns after prior EGFR-TKI therapy.
The study design is divided into two stages: The first stage is the safety lead-in phase, which plans to enroll 6 subjects. All subjects will receive ivonescimab in combination with their original EGFR-TKI regimen. After the last enrolled subject completes at least 21 days of observation following their first dose of study treatment, investigators will conduct a safety assessment and decide whether to enter the expansion phase with the current dose regimen. If the safety and tolerability profile is unacceptable, investigators will decide to revise or terminate the study, and may adjust the dosing regimen of ivonescimab and/or EGFR-TKIs. A total of 30 subjects are planned to be enrolled in the expansion phase.
All enrolled patients will receive ivonescimab in combination with their original EGFR-TKI regimen, with every 3 weeks constituting one treatment cycle. Treatment will continue until disease progression, intolerable toxicity, investigator-initiated discontinuation, patient withdrawal of informed consent, or meeting other treatment discontinuation criteria specified in the protocol, whichever occurs first. During treatment, investigators will determine disease progression (PD) based on tumor response evaluated per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and decide whether the patient may continue study treatment. If the patient's performance status remains stable and the investigator judges that the patient can benefit from continued treatment, the patient may continue on study treatment. During the study, clinical tumor imaging assessment will be performed by investigators per RECIST v1.1 in accordance with routine clinical practice. For patients who discontinue treatment for reasons other than disease progression, follow-up of disease status will continue whenever possible until the patient initiates other anti-tumor therapy, develops disease progression, withdraws informed consent, dies, or the study concludes, whichever occurs first.
Investigators will assess the safety of ivonescimab in this study population. All adverse events (AEs) will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0), and the causal relationship between adverse events and study treatment will be determined.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Arm1 | Experimental | Drug: ivonescimab plus EGFR-TKI.All subjects will receive ivonescimab in combination with their original EGFR-TKI regimen. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 1. Voluntarily signed written informed consent form; 2. Age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 4. Expected survival ≥ 3 months; 5. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC), which is unresectable for complete surgical resection and not eligible for radical concurrent/sequential chemoradiotherapy, staged per the 8th edition TNM Staging for Lung Cancer released by the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC); 6. Positive EGFR sensitive activating mutation confirmed by tumor histology, cytology or hematology testing before enrollment, including exon 19 deletion (19Del) and exon 21 point mutation (L858R); patients with EGFR T790M mutation are also eligible for enrollment; 7. Developed slow progression or potential progression during EGFR-TKI therapy: 8. Presence of at least one measurable lesion; 9. Normal function of major organs, meeting all the following criteria:
- Routine blood test results meet the requirements (no blood transfusion, no use of hematopoietic growth factors, no drug correction within 14 days before testing):
- Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L (1,500/mm³); b. Platelet count (PLT) ≥ 90×10⁹/L (90,000/mm³); c. Hemoglobin (HB) ≥ 90 g/L; 10. Biochemical test results meet the following criteria:
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN;
- Serum albumin (ALB) ≥ 28 g/L;
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ivonescimab plus EGFR-TKI.All subjects will receive ivonescimab in combination with their original EGFR-TKI regimen. | Drug | Arm1 |
Primary outcome
PFS
Time frame: From randomization through to the end of study, planned duration was 20 months
PFS was defined as the interval from diagnosis to disease progression or death from any cause.
1 secondary outcome
OS
Time frame: From randomization through to the end of study, planned duration was 20 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for NSCLC (Advanced Non-small Cell Lung Cancer)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
RecruitingPhase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
RecruitingPhase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jinming Yu, Dr study director
Shandong Cancer Hospital and Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ivonescimab plus EGFR-TKI. in people with NSCLC (Advanced Non-small Cell Lung Cancer), run by Shandong Cancer Hospital and Institute at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PFS (time frame: From randomization through to the end of study, planned duration was 20 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.